MEIP MEI Pharma
- 3.0800
- +0.1500+5.12%
MEI Pharma News
Stifel Nicolaus Reaffirms Their Hold Rating on MEI Pharma (MEIP)
MEI Pharma (MEIP.US): The 2024 Q3 financial report achieved revenue of $0, with a previous value of US$5.894 million, with an expected value of US$40,000; earnings per share of -1.37 USD, previous value of -2.32 USD, and expected value of -1.52 USD.
MEI Pharma (MEIP.US): The 2024 Q3 financial report achieved revenue of $0, with a previous value of US$5.894 million, with an expected value of US$40,000; earnings per share of -1.37 USD, previous value of -2.32 USD, and expected value of -1.52 USD.
MEI Pharma Q3 2024 Adj EPS $(1.37) Beats $(1.52) Estimate, Sales $5.890M Beat $37.500K Estimate
MEI Pharma (NASDAQ:MEIP) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.52) by 9.87 percent. The company reported quarterly sales of $5.890 million wh
MEI Pharma | 10-Q: Quarterly report
Press Release: MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights -- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Comp
MEI Pharma 3Q Loss/Shr $1.37 >MEIP
MEI Pharma 3Q Loss/Shr $1.37 >MEIP
Stifel: Maintaining the MEI Pharma (MEIP.US) rating, adjusted from holding to holding rating, and adjusting the target price from $7.00 to $7.00.
Stifel: Maintaining the MEI Pharma (MEIP.US) rating, adjusted from holding to holding rating, and adjusting the target price from $7.00 to $7.00.
Stifel Maintains Hold on MEI Pharma, Maintains $7 Price Target
Stifel analyst Stephen Willey maintains MEI Pharma (NASDAQ:MEIP) with a Hold and maintains $7 price target.
MEI Pharma Shelves Plans for a Second Return of Capital
MEI Pharma Aligns On Strategy To Advance Voruciclib And ME-344
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritiz
MEI Pharma Reports Initial Data From Clinical Study Evaluating ME-344 In Combination With Bevacizumab In Relapsed Metastatic Colorectal Cancer Patients
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study –– ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.
Biotech Bankruptcies Hit a Record Despite Sector's Recovery
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
MEI Pharma Announces Flexible $25 Million Funding Strategy
MEI Pharma Files for $100M Mixed Shelf
5 Value Stocks In The Healthcare Sector
What is a Value Stock?A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators
MEI Pharma Price Target Cut to $7.00/Share From $8.00 by Stifel
MEI Pharma Price Target Cut to $7.00/Share From $8.00 by Stifel
MEI Pharma Is Maintained at Hold by Stifel
MEI Pharma Is Maintained at Hold by Stifel
MEI Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/14/2024 54.19% Stifel $8 → $7 Maintains Hold 09/27/2023 98.24% Stifel $10 → $9 Maintains Hold 05/23/202
Analysis
Price Target
No Data
